This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LAMBERTS, S. W. J. Articles by QUIK, R. F. P. Search for Related Content PubMed PubMed Citation Articles by LAMBERTS, S. W. J. Articles by QUIK, R. F. P.

A Comparison of the Efficacy and Safety of Pergolide and Bromocriptine in the Treatment of Hyperprolactinemia^*

Department of Medicine, Erasmus University, Rotterdam, and Lilly Research Centre Windlesham, Surrey, United Kingdom

Address correspondence and requests for reprints to: Steven W. J. Lamberts, M.D., Professor of Medicine, Department of Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD Rotterdam, The Netherlands.

Pergolide is a synthetic ergoline derivative with highly potent long-acting PRL-lowering activity, allowing therapy of hyperprolactinemia with a once daily administration of the drug. The results of two open-label, randomized controlled multicenter clinical trials are reported. Pergolide (taken once a day), was compared with bromocriptine (taken two to four times daily) regarding efficacy and safety in the reduction of PRL levels, the cessation of galactorrhea and amenorrhea, the improvement in sexual function, and tumor shrinkage in hyperprolactinemia without (trial I; 61 patients) and with radiologically evident pituitary tumors (trial II; 96 patients).

Both drugs were equally effective in lowering PRL levels in both trials. A median optimal dose of 50 µg pergolide and 5 mg bromocriptine/day suppressed PRL levels in the 61 patients of trial I by more than 80%. During the 24-week investigational period galactorrhea disappeared in 96% and 87% of patients, whereas menstruation returned in 90% and 96% of patients, respectively. An equally high efficacy (optimal median dose: 75–100 µg pergolide, 7.5–10 mg bromocriptine daily) was observed in trial II, although the resumption of menses was less frequent than in the patients of trial I (50% and 58% of patients, respectively). Sexual dysfunction improved similarly on both drugs in about half the patients. In addition, tumor shrinkage occurred to a similar extent with both drugs.

A high incidence of adverse events was noted especially at the initiation of therapy with both compounds: nausea, dizziness, vomiting, asthenia, headache, and decrease in blood pressure occurred at a similar incidence and extent during the use of pergolide and bromocriptine. Patients in trial I treated with pergolide reported a slightly higher incidence of fever, vasodilatation, and flu syndrome.

Conclusions: in these 24-week studies comprising a total of 157 hyperprolactinemic patients, a once daily administration of pergolide was shown to be as safe and effective as the two to four times daily ingestion of bromocriptine. Longer-acting dopamine agonists like pergolide that can be taken once daily, are likely to increase the ease to adherence to the therapeutic regimen. This might result in a higher compliance to medical treatment of hyperprolactinemia.

^* This study was financially supported by Eli Lilly & Company, Indianapolis, IN.

Received May 16, 1990.

This article has been cited by other articles:

				M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]

				P. U. Freda, C. I. Andreadis, A. G. Khandji, M. Khoury, J. N. Bruce, T. P. Jacobs, and S. L. Wardlaw Long-Term Treatment of Prolactin-Secreting Macroadenomas with Pergolide J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 8 - 13. [Full Text]

				P. U. Freda and S. L. Wardlaw Diagnosis and Treatment of Pituitary Tumors J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3859 - 3866. [Full Text]

				M. E. Molitch, M. O. Thorner, C. Wilson, M. E. Molitch, M. D., M. O. Thorner, and C. Wilson The Case for Initial Surgical Removal of Certain Prolactinomas J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 996 - 1000. [Full Text] [PDF]

				O. Serri Progress in the Management of Hyperprolactinemia N. Engl. J. Med., October 6, 1994; 331(14): 942 - 944. [Full Text]